VitaNova Life Sciences Corp Cash Flow Statement
VNOV|10 years of annual SEC 10-K data (FY2016-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 10 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 3.24 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | - | $850.7K | $140.9K | -$24.2K | $139.7K | -$52.1K | -$72.3K | -$106.2K | -$1.6K | -$7.2K |
| Depreciation & Amortization | - | - | - | - | - | - | - | - | $0 | $40 |
| Operating Cash Flow | - | $192.8K | -$375.9K | -$18.4K | $4.1K | -$42.3K | -$53.6K | -$49.1K | -$9.3K | -$6.5K |